Speciality Medicines Ltd Annual General Meeting Update

Revenue grew to Rs 75.29 crore in FY26, with net profit surging to Rs 13.03 crore.

Reader Takeaway: Robust profit growth and low debt, but R&D project execution remains critical for future performance.

What just happened

Speciality Medicines Ltd successfully conducted its 5th Annual General Meeting on September 28, 2026. Shareholders adopted the audited financial statements for FY 2025-26 and approved the re-appointment of Mr. Sumit Babubhai Goyani as Director. The management provided a detailed briefing on the utilization of funds raised during its recent IPO.

Why this matters

The company’s financials demonstrate significant scaling. Net profit after tax jumped from Rs 7.20 crore in FY 2024-25 to Rs 13.03 crore in FY 2025-26. Revenue also grew steadily to Rs 75.29 crore, supported by a dual business model of contract manufacturing and domestic distribution.

Strategic Deployment

A significant portion of the IPO proceeds—Rs 12.68 crore—is dedicated to building a high-tech R&D center in Umargam, Gujarat. This facility will focus on advanced formulations including injectables and ophthalmic preparations, adhering to GLP standards. Additionally, Rs 8 crore is allocated for working capital and Rs 2.99 crore for international product registrations.

Operational Health

Speciality Medicines Ltd maintains a conservative balance sheet with a debt-to-equity ratio of 0.34x and a strong current ratio of 4.73x. The company now services over 35 countries, indicating a broad global footprint that mitigates localized market risks.

What to track next

Investors should closely monitor the construction timelines for the Gujarat R&D center. Success in obtaining international product registrations and maintaining the current export-domestic sales balance will be key drivers for valuation in the coming quarters.